Deloitte China assists listing of InSilico Medicine on SEHK
HK’s largest biotech IPO in 2025
Deloitte China supported the listing of InSilico Medicine (InSilico Medicine, stock code: 03696.HK) on the Stock Exchange of Hong Kong (SEHK) on 30 December 2025. InSilico Medicine’s listing has become Hong Kong’s largest biotech IPO in 2025 by funds raised.
In this global offering, InSilico Medicine offers 94.7million shares with each share at an offer price of HKD24.05, raising approximately HKD2.3 billion.
InSilico Medicine has brought in 15 institutional investors as the cornerstone investors, from which USD115 million is raised.
(From left) Dr. Alex Zhavoronkov, chairman of the board, executive director, founder, CEO and CBO of Insilico Medicine; Anna Chen, Tax partner of Deloitte China; David Yu, Chief Growth Officer of Deloitte China; Ernst Lee, Deloitte China’s Technical partner and a member of the Listing Committee of the SEHK; Calvin Chen, Audit & Assurance (A&A) partner; Dr. Feng Ren, executive director, CEO and CSO of Insilico Medicine and Peng Dai, head of Finance, vice president of Insilico Medicine attend the listing ceremony of InSilico Medicine at Hong Kong Stock Exchange.
(From left) Kimy Lin, A&A partner of Deloitte China; Anna Chen, Dr. Feng Ren, David Yu, Calvin Chen and Alison Shan, A&A manager attend the listing ceremony of InSilico Medicine at Hong Kong Stock Exchange.
David Yu, Dr. Alex Zhavoronkov, and representatives from other parties attend the listing ceremony.
Client overview
InSilico Medicine is a reputable and global AI-driven drug discovery and development company. Its business model is based on its proprietary generative AI platform, Pharma.AI that focuses on researching and developing drugs through AI.
To date, InSilico Medicine has generated more than 20 clinical or IND-enabling stage assets using Pharma.AI. The reach of Pharma. AI has been extended across diverse industries, such as advanced materials, agriculture, nutritional products, and veterinary medicine.
Deloitte's role
The company's listing has spanned industry cycles, bearing witness to the resilience of both the company's and Deloitte's teams. As a core service institution of this new listing engagement, Deloitte China has been deeply involved in the entire process of the IPO. This successful listing demonstrates Deloitte's professional service capabilities in serving clients in capital markets. Our engagement team worked closely with various professional parties, provided high-quality services with rich industry experience and excellent professional capabilities to assist InSilico Medicine’ listing on the Main Board of the SEHK.
Deloitte China congratulates InSilico Medicine on its successful listing on the SEHK. We will continue to provide high quality professional services and outstanding resources integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see About Deloitte to learn more.
Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.
We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.
The Deloitte brand originated in 1845, and its name in Chinese (德勤) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.
This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.
No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.
